TCTR20210421004尚未招募3 期
Efficacy of Optimal dose of Regional Citrate Anticoagulation versus saline flushing in preventing blood circuit clot for intermittent hemodialysis ; A Prospective Randomized Clinical Trial
适应症
试验速览
- 阶段
- 3 期
- 状态
- 尚未招募
- 入组人数
- 30
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 Years 至 100 Years（—）
- 性别
- All
入选标准
- •Acute setting ; AKI,ESRD
- •Age > 18 yrs
- •Informed consent
- •Undergoing central venous catheters or AVF/AVG, by prescription HD: Low flux dialyzer
- •BFR 200 ml/min
- •Dialyzate Ca 1.75 mEq/L
- •Duration 4 hr
排除标准
- •1.Patients were treated withantiplatelet,oral anticoagulant therapyorotherdrugs known to affect coagulation within 7 days
- •2. Acute liver failure
- •4. Contraindication to systemicanticoagulation:
- •Abnormal plasmatotal calcium <7.0 mg/dL
- •Abnormal plasmatotal magnesium <1.8 mg/dL
- •Abnormal plasmatotal sodium >145 mg/dL
- •metabolic alkalosis; serum bicarb > 28 mEq/L
- •Known allergy to citrate
- •Documented arrhythmia
研究者
相似试验
尚未招募
3 期
Efficacy of Regional Citrate Anticoagulation versus SalineFlushingduring Intermittent Hemodialysis on blood circuit clotting prevention;A Randomized Clinical Trialhypocalcemia hypernatremia metabolic alkalosis cardiac arrhythmiaRegional citrate anticoagulants Saline flushing intermittent hemodialysisTCTR20210929007Bhumibol Adulyadej Hospital42
已完成
不适用
Regional citrate anti-coagulation for continuous renal replacement therapy in patients with acute kidney injuryAcute kidney injuryACTRN12611000099921Department of intensive care, Pamela Youde Nethersole Eastern Hospital10
进行中（未招募）
不适用
Phase I and II perspective study with Citrate in Liposoma not Pegilate Doxorubicine TLC D-99 in association to Ifosfamide in patients with metastatic soft tissue sarcoma.TREATMENT OF PATIENTS AFFECTED WITH SOFT TISSUE SARCOMA IN METASTATIC PHASEMedDRA version: 9.1Level: PTClassification code 10039491Term: SarcomaEUCTR2005-004569-40-ITISTITUTO CLINICO HUMANITAS52
进行中（未招募）
不适用
Evaluation of the optimal dose of prophylactic anticoagulation with low- molecular- weight heparin administered subcutaneously to critically ill patients – part 2 - LMWH prophylaxis for ICU patientsMedDRA version: 12.1Level: LLTClassification code 10049909Term: Venous thromboembolism prophylaxisvenous thromboembolismEUCTR2010-022034-88-DKOdense University Hospital
进行中（未招募）
1 期
Evaluation of the optimal dose of prophylactic anticoagulation with low-molecular-weight heparine administered subcutaneously to critically ill patients - low-molecular-weight heparin in critically ill patientsEUCTR2005-002381-10-DKDept anaesthesiology and intensive care80